| Literature DB >> 34894102 |
Vojtěch Illinger1, Ondřej Materna2, Kryštof Slabý1, Denisa Jičínská2, Jan Kovanda2, Karel Koubský2, Jan Pokorný1, Michal Procházka1, Petra Antonová3, Antonín Hoskovec4, Jiří Radvanský1, Václav Chaloupecký2, Jan Janoušek2.
Abstract
AIMS: Fontan palliation is a surgical strategy for patients with complex congenital heart disease, in whom biventricular circulation cannot be achieved. Long-term survival is negatively affected by the absence of sub-pulmonary ventricle and increased systemic venous pressure. Exercise capacity is a known predictor of overall survival and quality of life in congenital heart defects. We aim to track individual trends of peak oxygen uptake (V̇O2 peak) after total cavopulmonary connection (TCPC), identify predictors of deterioration, and derive a disease-specific reference V̇O2 peak dataset. METHODS ANDEntities:
Keywords: Cardiopulmonary exercise testing; Exercise capacity; Fontan circulation; Oxygen consumption; Total cavopulmonary connection
Mesh:
Year: 2021 PMID: 34894102 PMCID: PMC8788045 DOI: 10.1002/ehf2.13747
Source DB: PubMed Journal: ESC Heart Fail ISSN: 2055-5822
Main diagnosis
| Diagnosis | Count ( | % |
|---|---|---|
| Tricuspid atresia | 67 | 23.3 |
| Single ventricle/double‐inlet left ventricle | 52 | 18.1 |
| Double‐outlet right ventricle | 51 | 17.7 |
| Hypoplastic left heart syndrome | 26 | 9.0 |
| Transposition of the great arteries | 18 | 6.2 |
| Single ventricle/double‐inlet right ventricle | 18 | 6.2 |
| Mitral atresia | 16 | 5.6 |
| Pulmonary atresia with intact interventricular septum | 14 | 4.9 |
| Congenitally corrected transposition of the great arteries | 9 | 3.1 |
| Complete atrioventricular septal defect | 6 | 2.1 |
| Hypoplastic right ventricle | 3 | 1.0 |
| Other | 8 | 2.8 |
| Total | 288 | 100.0 |
List of pharmacotherapies
| Pharmacotherapy | Count ( | % |
|---|---|---|
| Angiotensin‐converting enzyme inhibitors | 90 | 31.2 |
| Digoxin | 41 | 14.2 |
| Furosemide | 22 | 7.6 |
| Beta‐blockers | 18 | 6.3 |
| Spironolactone | 9 | 3.1 |
| Propafenone | 4 | 1.4 |
| Sotalol | 4 | 1.4 |
| Sildenafil | 4 | 1.4 |
| Bosentan | 3 | 1.0 |
| Calcium channel blockers | 1 | 0.3 |
Figure 1V̇O2peak quantile regression in men with percentiles, the total number of tests (N = 434).
Figure 2V̇O2peak quantile regression in women with percentiles, the total number of tests (N = 312).
Figure 3Oxygen pulse increase during exercise in men with total cavopulmonary connection (blue) compared to healthy controls (black). ns, non‐significant; Wmax, maximal power output in watts. ****P < 0.00001.
Figure 4Oxygen pulse increase during exercise in women with total cavopulmonary connection (red) compared to healthy controls (black). ns, non‐significant; Wmax, maximal power output in watts. *P < 0.01. ****P < 0.00001.
Figure 5Individual linear trajectories of V̇O2peak fitted by the method of least squares from first to last cardiopulmonary exercise test and calculated means for both genders (grey lines for individual trajectories, blue line for mean decline rate in men, and red line for mean decline rate in women). **P < 0.001.